Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemogenesis of an antiangiogenic glycosaminoglycan.

Literature DB >> 24944736

Chemogenesis of an antiangiogenic glycosaminoglycan.

Karthik Raman¹, Sailaja Arungundram², Balagurunathan Kuberan³.

Abstract

In this letter we report a facile chemical conversion of heparin, a potent anticoagulant with minimal antiangiogenic activity, into an effective antiangiogenic glycosaminoglycan through optimized chemical approaches. This work highlights the potential for industrial scale production of a therapeutic anticancer glycosaminoglycan.

Entities: Chemical

Keywords: Acharan sulfate; angiogenesis; heparan sulfate; heparin; synthesis

Year: 2014 PMID： 24944736 PMCID： PMC4060934 DOI： 10.1021/ml400498d

Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.345

Keyword Cloud
References

18 in total

1. Importance of 6-O-sulfate groups of glucosamine residues in heparin for activation of FGF-1 and FGF-2.

Authors: M Ishihara; R Takano; T Kanda; K Hayashi; S Hara; H Kikuchi; K Yoshida
Journal: J Biochem Date: 1995-12 Impact factor: 3.387

Review 2. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate.

Authors: Steven D Rosen; Hassan Lemjabbar-Alaoui
Journal: Expert Opin Ther Targets Date: 2010-09 Impact factor: 6.902

3. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding.

Authors: H Wang; T Toida; Y S Kim; I Capila; R E Hileman; M Bernfield; R J Linhardt
Journal: Biochem Biophys Res Commun Date: 1997-06-18 Impact factor: 3.575

Review 4. Tumor angiogenesis: therapeutic implications.

Authors: J Folkman
Journal: N Engl J Med Date: 1971-11-18 Impact factor: 91.245

5. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.

Authors: Michele Basche; Daniel L Gustafson; Scott N Holden; Cindy L O'Bryant; Lia Gore; Samir Witta; Mary Kay Schultz; Mark Morrow; Adrah Levin; Brian R Creese; Michael Kangas; Kaye Roberts; Thu Nguyen; Kat Davis; Russell S Addison; Jane C Moore; S Gail Eckhardt
Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531

Review 6. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies.

Authors: Levon M Khachigian; Christopher R Parish
Journal: Cardiovasc Drug Rev Date: 2004

Chemogenesis of an antiangiogenic glycosaminoglycan.

1. Importance of 6-O-sulfate groups of glucosamine residues in heparin for activation of FGF-1 and FGF-2.

Review 2. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate.

3. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding.

Review 4. Tumor angiogenesis: therapeutic implications.

5. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.

Review 6. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies.

7. Synthesis of Fondaparinux: modular synthesis investigation for heparin synthesis.

Review 8. The repertoire of glycan determinants in the human glycome.

9. Inhibition by acharan sulphate of angiogenesis in experimental inflammation models.

10. Determination of the structure of oligosaccharides prepared from acharan sulfate.